Abstract | PURPOSE: METHODS: RESULTS: The concentration and penetration rate of gefitinib (mean ± standard deviation) in the CSF were 3.7 ± 1.9 ng/mL (8.2 ± 4.3 nM) and 1.13 ± 0.36 %, respectively. The concentration and penetration rate of erlotinib in the CSF were 28.7 ± 16.8 ng/mL (66.9 ± 39.0 nM) and 2.77 ± 0.45 %, respectively. The CSF concentration and penetration rate of erlotinib were significantly higher than those of gefitinib (P = 0.0008 and <0.0001, respectively). The CNS response rates of patients with erlotinib treatment were preferentially (but not significantly) higher than those with gefitinib treatment. (1/3 vs. 4/7, respectively). Leptomeningeal metastases in one patient, which were refractory to gefitinib, dramatically responded to erlotinib. CONCLUSIONS:
|
Authors | Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim, Toshiya Katsura, Michiaki Mishima |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 70
Issue 3
Pg. 399-405
(Sep 2012)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 22806307
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
- Gefitinib
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(blood, cerebrospinal fluid, therapeutic use)
- Asian People
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Central Nervous System Neoplasms
(drug therapy, secondary)
- Chromatography, High Pressure Liquid
- ErbB Receptors
(genetics)
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Japan
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Meningeal Neoplasms
(drug therapy, secondary)
- Middle Aged
- Mutation
- Quinazolines
(administration & dosage)
- Tandem Mass Spectrometry
- Treatment Outcome
|